An in-depth look at this medical topic, providing essential context for patients and caregivers.
General Medical Overview
Hepatoblastoma: A condition categorized under Rare Abdominal & Miscellaneous.
Hepatoblastoma is the most common primary liver malignancy in children, typically presenting before age 3. It arises from hepatocyte precursor cells and is associated with very high AFP (alpha-fetoprotein) levels. Hepatoblastoma is highly chemosensitive, and modern risk-stratified protocols achieve cure rates exceeding 80%.
Typical Treatment Roadmap
Detection
Symptoms and initial checkup.
Diagnosis
Biopsy and clinical imaging.
Treatment
Therapy (Surgery, Chemo, etc.)
Monitoring
Follow-up and recovery.
Clinical Manifestation (Main Symptoms)
Clinically, the initial presentation of Hepatoblastoma often manifests with Fatigue, Weight Loss, Pain and Indigestion.
Advanced Stage Signs (Warning)
Palpable abdominal mass, abdominal distension, anorexia, weight loss, and markedly elevated serum AFP (often >1,000 ng/mL).
Diagnostic Procedures
Abdominal ultrasound/CT/MRI showing liver mass with calcifications, markedly elevated AFP (diagnostic in the appropriate clinical context — biopsy may not be needed), and PRETEXT staging (pre-treatment extent of disease).
Medical Risk Factors
Beckwith-Wiedemann syndrome, familial adenomatous polyposis (FAP), very low birth weight (<1,500g), and trisomy 18.
Therapeutic Approach
Neoadjuvant cisplatin-based chemotherapy (PLADO or C5VD protocols) to downstage tumor. Surgical resection (partial hepatectomy or liver transplant for unresectable tumors). Adjuvant chemotherapy to complete protocol. Liver transplant for centrally located tumors involving all liver sectors.
Medical Breakthroughs & Hope
Hepatoblastoma is one of the most curable childhood solid tumors. Even tumors initially deemed unresectable can be cured through a combination of effective chemotherapy and liver transplantation.
Prognosis & Efficacy45%
Standard-risk hepatoblastoma has >90% 5-year survival. High-risk disease (metastatic) has approximately 60-70% survival. Overall cure rates exceed 80% with modern chemotherapy and surgical approaches including liver transplantation.
Myth vs. Clinical Reality
Myth / Fiction
Liver cancer in children is hopeless.
Fact / Reality
Hepatoblastoma has >80% cure rate with modern treatment, including chemotherapy, surgery, and transplant when needed.
Myth / Fiction
Liver transplant is too risky for a child.
Fact / Reality
Pediatric liver transplantation has excellent outcomes with >85% long-term survival. For unresectable hepatoblastoma, it is a life-saving curative option.
Frequently Asked Questions (FAQ)
Can a child receive a liver transplant for cancer?
Yes. Liver transplantation is an established curative option for hepatoblastoma that cannot be resected by partial hepatectomy due to central location or multi-sectoral involvement.
What is AFP?
Alpha-fetoprotein is normally high in infants but markedly elevated (often >10,000) in hepatoblastoma. It serves as a very sensitive tumor marker for diagnosis and monitoring treatment response.
Is hepatoblastoma related to adult liver cancer?
No. Hepatoblastoma is a pediatric embryonal tumor distinct from adult hepatocellular carcinoma. It has different biology, treatment, and prognosis.
Why is PRETEXT staging important?
PRETEXT defines which liver sectors are involved before chemotherapy, guiding surgical planning and risk stratification. It helps determine whether partial hepatectomy or transplant is needed.
Can children live normally after liver resection?
Yes. The liver has remarkable regenerative capacity — even after removing 60-70% of the liver, it regenerates within weeks. Most children recover fully and live normal lives.